Dimensions of response to antidepressant agents in bulimia nervosa: A review
โ Scribed by Barbara E. Wolfe
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 864 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1532-8228
No coin nor oath required. For personal study only.
โฆ Synopsis
Many patients suffering from bulimia nervosa benefit from treatment with antidepressant medication. Nurses, like other mental health clinicians, tend to assess the effectiveness of a pharmacologic agent in patients with bulimia nervosa by the decline in the frequency of binge eating episodes. Clinical descriptions and research reports suggest the possibility of additional behavioral dimensions of treatment responsiveness, although the extent to which associated behaviors or symptoms improve is not well documented. This paper examines 16 placebocontrolled pharmacological trials in patients with bulimia nervosa to evaluate a range of potential measures of response to antidepressant intervention.
๐ SIMILAR VOLUMES
## Objective: The aim of this provocation study was to examine insulin, glucose, and cortisol levels in response to a glucose load in bulimia nervosa patients and to relate this to behavior, treatment status, and depressive symptomatology. Method: A 3-hr glucose tolerance test was performed in 15 f
## Objective: To examine characteristics of individuals who show a rapid and sustained response to cognitive-behavioral therapy (cbt) for bulimia nervosa (bn). ## Method: As part of a randomized clinical trial designed to dismantle cbt for bn, we compared 19 individuals who exhibited complete abs
A 25-year-old female patient with a 9-year history of bulimia nervosa gave a 2-year history of regularly ingesting up to 24 ร 300 mg aspirin tablets to facilitate vomiting after a binge. Awareness of this dangerous practice is important when asking for an eating disorder history. Assessing for the p